The safety of abatacept was studied using patients with rheumatoid arthritis (RA) from 7 European registers, revealing safety signals on par with that previously reported with no new safety concerns. 

Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients.

Another study has confirmed that the intestinal microbiome's composition in people with inflammatory arthritis differs from that in other people, and in potentially unhealthy ways -- but whether the microbiome alterations actually cause arthritis is less clear.  In fact, the investigato

Large scale analysis of adverse events (AEs) in World Health Organization (WHO) VigiAccess database showed no new safety signals associated with long-standing use of five TNFα inhibitors. 

A UK registry study of moderate to severe systemic lupus erythematosus (SLE) patients showed that treatment with rituximab or belimumab was not associated with a greater risk of serious infection, when compared to standard of care therapy.

In 2018, Park et al showed optimal responses to influenza vaccination in RA patients was best achieved by holding methotrexate for 2 weeks following immunization, with improved humoral responses. Now, a followup trial suggests that equivalent results are had by holding MTX for only 1 week with the "flu" vaccine.

Dr. Jack Cush Reviews the news and journal reports on CVA, TKA, PJP, ADA, and more!

Do abatacept, cenicriviroc, or infliximab improve time to recovery for patients hospitalized with COVID-19 pneumonia compared with standard care?

Safety outcomes for targeted synthetic or biological disease-modifying antirheumatic drugs (b/ts DMARDs) used to treat RA were studied using data from the Anti-Rheumatic Therapies in Sweden (ARTIS) registry, showing that these newer agents are largely similar, but still have particular differences for specific infection or other adverse event risks.

Recurrent bouts of systemic lupus erythematosus, marked by the body’s immune system attack of its own tissues, closely tracked with measurable upticks in growth in the gut of a certain species of bacteria.

Dr. Jack Cush reviews the news and reports from the past week on RheumNow.com. This week a new colchicine FDA approval, rising rate of IgG4 related disease and what's the safest biologic?

A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.

One of the primary questions about JAK inhibitor safety, ever since its first approval, has been the risk of herpes zoster.